Extended survival has been seen, however, in a subgroup of AIDS patients with CD4 counts of more than 200 and no concurrent opportunistic infections, who can tolerate aggressive therapy consisting of either methotrexate monotherapy or vincristine, procarbazine, or whole brain radiotherapy. These patients have a median survival of 10–18 months.
Although prolonged survival has been noted in some AIDS patients with high CD4 counts and no concurrent opportunistic infections, these individuals can tolerate aggressive treatment regimens consisting of methotrexate monotherapy or vincristine, procarbazine, or whole brain radiotherapy. The median survival time for this group is 10–18 months.